SG Americas Securities LLC Makes New $172,000 Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)

SG Americas Securities LLC acquired a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 12,938 shares of the company’s stock, valued at approximately $172,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. grew its position in Dyne Therapeutics by 8.9% during the 1st quarter. Principal Financial Group Inc. now owns 11,619 shares of the company’s stock worth $134,000 after purchasing an additional 950 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Dyne Therapeutics by 6.1% during the 1st quarter. Deutsche Bank AG now owns 19,517 shares of the company’s stock valued at $225,000 after buying an additional 1,117 shares during the period. Ameritas Investment Partners Inc. boosted its stake in shares of Dyne Therapeutics by 49.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,510 shares of the company’s stock valued at $39,000 after buying an additional 1,155 shares during the period. Credit Suisse AG boosted its stake in shares of Dyne Therapeutics by 10.6% during the 2nd quarter. Credit Suisse AG now owns 18,015 shares of the company’s stock valued at $124,000 after buying an additional 1,729 shares during the period. Finally, Rhumbline Advisers boosted its stake in shares of Dyne Therapeutics by 4.0% during the 1st quarter. Rhumbline Advisers now owns 51,180 shares of the company’s stock valued at $590,000 after buying an additional 1,966 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, major shareholder Venture Fund Xi L.P. Atlas sold 184,501 shares of Dyne Therapeutics stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $22.57, for a total value of $4,164,187.57. Following the transaction, the insider now owns 6,631,464 shares in the company, valued at approximately $149,672,142.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Jason P. Rhodes sold 119,360 shares of the business’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $22.66, for a total transaction of $2,704,697.60. Following the transaction, the director now owns 6,512,104 shares in the company, valued at approximately $147,564,276.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Venture Fund Xi L.P. Atlas sold 184,501 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $22.57, for a total transaction of $4,164,187.57. Following the transaction, the insider now owns 6,631,464 shares in the company, valued at approximately $149,672,142.48. The disclosure for this sale can be found here. Insiders have sold 1,888,532 shares of company stock worth $44,687,450 in the last quarter. 32.89% of the stock is currently owned by company insiders.

Dyne Therapeutics Trading Down 5.6 %

DYN stock opened at $25.85 on Monday. Dyne Therapeutics, Inc. has a 1 year low of $6.40 and a 1 year high of $30.27. The company has a fifty day simple moving average of $25.78 and a 200 day simple moving average of $16.82. The firm has a market cap of $2.23 billion, a PE ratio of -6.56 and a beta of 0.95.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, March 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.17). As a group, analysts forecast that Dyne Therapeutics, Inc. will post -3.25 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on DYN. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, March 6th. Stifel Nicolaus lifted their target price on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Chardan Capital lifted their target price on shares of Dyne Therapeutics from $20.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, March 8th. Oppenheimer reaffirmed an “outperform” rating and issued a $47.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, March 26th. Finally, Raymond James lifted their price objective on shares of Dyne Therapeutics from $27.00 to $56.00 and gave the company a “strong-buy” rating in a research note on Thursday, January 4th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Dyne Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $37.43.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.